A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body. In this study, all participants will receive the study drug, which will be taken by mouth (orally).

Trial Details

NCT ID
NCT06305247
Phase
PHASE1 / PHASE2
Sponsor
Ipsen
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • IPN01194
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • San Diego, California, United States|32.71571,-117.16472
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • Fairfax, Virginia, United States|38.84622,-77.30637

Key Eligibility Criteria

  • Participants must be ≥18 years of age
  • Participants with histologically confirmed metastatic solid tumour (melanoma, metastatic colorectal cancer (CRC), pancreatic ductal adenocarcinoma …
  • Participants must bear tumours harbouring selected classes of genetic mutations, (MAPKm).
  • Participants must have measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →